Lumonus has successfully closed a Series B financing round, raising A$25 million to enhance its AI-powered radiation oncology workflow solutions. The funding, announced on November 7, 2025, was led by Aviron Investment Management with continued backing from Oncology Ventures. This investment underscores the growing clinical adoption of Lumonus AI across leading health systems in the United States, Australia, and Europe.
The Lumonus AI platform has already facilitated over 280,000 cancer treatments and automated the creation of more than 75,000 treatment plans. These figures highlight the platform’s significant role in streamlining oncology workflows, ultimately boosting the efficiency and consistency of patient care. With a leadership team that combines over 100 years of experience in clinical, operational, and technical aspects of oncology, Lumonus aims to transform how cancer care is delivered.
Keith Hansen, Chief Executive Officer of Lumonus, emphasized the current state of oncology, stating, “Oncology is at an inflection point. Scientific innovation in cancer treatment has advanced significantly, but the systems that support teams delivering the care have not kept pace.” He noted that the investment will allow Lumonus to expand its team and support more health systems ready to embrace improved oncology workflows.
The Chairman of Lumonus, Merrick Howes, remarked on the milestone, saying, “This milestone reflects the dedication of our entire team, who have worked side by side with clinicians worldwide.” He expressed confidence that the AI-native platform would continue to enhance clinical quality and operational efficiency, driving further innovation in cancer care.
The funds from this Series B round will be directed towards expanding Lumonus’s market presence in the United States and enhancing its key products, including Lumonus AI Physician and Lumonus AI Dosimetry. The company also plans to invest in clinical informatics capabilities, which will enable it to harness real-world evidence for improved quality and personalized care.
Ben Freeberg, Managing Partner at Oncology Ventures, praised the Lumonus team’s unique combination of clinical expertise and product execution. He noted the firm’s commitment to supporting Lumonus as it sets new standards in oncology workflows.
As Lumonus continues to advance its AI-integrated solutions, the company remains focused on collaborating with health systems to improve operational performance and deliver tailored, data-driven care. For more information about Lumonus and its initiatives, visit www.lumonus.com.
About Lumonus: Lumonus AI is redefining cancer care through its innovative digital oncology platform. By automating and orchestrating critical oncology workflows, Lumonus aims to enhance care quality, accelerate treatment delivery, and reduce administrative burdens. The company operates across the United States, Australia, and Europe.
About Aviron Investment Management: Aviron Investment Management is a private investment firm that specializes in the healthcare and technology sectors. Committed to fostering high-growth companies, Aviron provides strategic capital and operational insights to help businesses scale impactful solutions.
About Oncology Ventures: Based in New York, Oncology Ventures is a venture capital firm dedicated to advancing innovation in cancer care. The firm focuses on early-stage companies that develop technologies aimed at enhancing the accessibility and efficiency of oncology services.
